Complications of Treatment with CC DRG Reimbursement Guidance

DRG 920 covers admissions for complications of medical or surgical treatment with a Complication or Comorbidity, typically requiring additional interventions or monitoring. It matters for inpatient reimbursement because it groups these higher-resource cases separately for Medicare payment and case-mix adjustment.

DRG 920 Overview

DRG 920 encompasses inpatient admissions primarily for complications of medical or surgical treatment where a Complication or Comorbidity is present. These cases often involve additional diagnostic evaluation, medical management, or procedural intervention to address treatment-related adverse events. This Diagnosis-Related Group affects Medicare payment because it groups resource use for treatment complications separately from routine care, influencing reimbursement levels and hospital case-mix reporting. Understanding the clinical scope helps clarify why these admissions are categorized distinctly for Medicare inpatient reimbursement.

Acute procedural safety and mitigation studies: Trials focused on procedural and peri-procedural interventions to prevent or rapidly manage complications that occur during inpatient treatments (for example, hemorrhage control protocols, device-related injury response algorithms, or strategies to reduce intraoperative bacterial contamination). These studies enroll patients who develop acute, treatment-related complications requiring critical-care resources and evaluate immediate interventions, monitoring protocols, or rescue techniques. Findings guide clinicians on best practices to reduce ICU stays and high-cost resource utilization, and inform payers about interventions that can shorten lengths of stay or prevent escalation of care.
Comparative effectiveness research on management pathways: Studies comparing different inpatient management strategies for common treatment-related complications (such as conservative management versus interventional procedures, different antibiotic stewardship approaches for device-associated infections, or choice of anticoagulation reversal tactics). These trials typically include a heterogeneous inpatient population with complications from diverse index therapies and assess outcomes like complication resolution, need for reoperation, readmission, and complication-related costs. Results are directly relevant for providers selecting evidence-based care pathways and for payers assessing which management approaches offer the best balance of clinical benefit and cost-effectiveness.
Post-discharge outcomes and readmission prevention studies: Observational cohorts and implementation studies that follow patients discharged after treatment-related complications to evaluate long-term functional outcomes, complication recurrence, patient-reported quality of life, and drivers of readmission. These studies focus on transitions of care, outpatient monitoring strategies, and targeted follow-up interventions for high-risk subgroups (for example, patients with device-related complications or those who required prolonged inpatient support). Insights help health systems design discharge planning and post-acute services to reduce readmissions and downstream costs, which are critical metrics for payers managing episodes of care.

Acute procedural safety and mitigation studies: Trials focused on procedural and peri-procedural interventions to prevent or rapidly manage complications that occur during inpatient treatments (for example, hemorrhage control protocols, device-related injury response algorithms, or strategies to reduce intraoperative bacterial contamination). These studies enroll patients who develop acute, treatment-related complications requiring critical-care resources and evaluate immediate interventions, monitoring protocols, or rescue techniques. Findings guide clinicians on best practices to reduce ICU stays and high-cost resource utilization, and inform payers about interventions that can shorten lengths of stay or prevent escalation of care.
Comparative effectiveness research on management pathways: Studies comparing different inpatient management strategies for common treatment-related complications (such as conservative management versus interventional procedures, different antibiotic stewardship approaches for device-associated infections, or choice of anticoagulation reversal tactics). These trials typically include a heterogeneous inpatient population with complications from diverse index therapies and assess outcomes like complication resolution, need for reoperation, readmission, and complication-related costs. Results are directly relevant for providers selecting evidence-based care pathways and for payers assessing which management approaches offer the best balance of clinical benefit and cost-effectiveness.
Post-discharge outcomes and readmission prevention studies: Observational cohorts and implementation studies that follow patients discharged after treatment-related complications to evaluate long-term functional outcomes, complication recurrence, patient-reported quality of life, and drivers of readmission. These studies focus on transitions of care, outpatient monitoring strategies, and targeted follow-up interventions for high-risk subgroups (for example, patients with device-related complications or those who required prolonged inpatient support). Insights help health systems design discharge planning and post-acute services to reduce readmissions and downstream costs, which are critical metrics for payers managing episodes of care.

OpenPayer

Summary & Overview

Complications of Treatment with CC: Inpatient Reimbursement Overview

DRG 920 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes